A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
Status: Active_not_recruiting
Location: See all (53) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
• Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
• Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.
Locations
United States
Alabama
Cahaba Dermatology Skin Health Center
Birmingham
Velocity Clinical Research, Mobile
Mobile
California
Center for Dermatology Clinical Research
Fremont
Antelope Valley Clinical Trials
Lancaster
Northridge Clinical Trials
Northridge
NorthBay Clinical Research
Santa Rosa
Integrated Research of Inland
Upland
FOMAT Medical Research
Ventura
Florida
AMR Fort Myers
Fort Myers
Advanced Clinical Research Institute
Tampa
Iowa
The Iowa Clinic
West Des Moines
Illinois
Sneeze, Wheeze & Itch Associates LLC
Normal
Indiana
The Indiana Clinical Trials Center
Plainfield
Kansas
Hutchinson Clinic
Hutchinson
Kentucky
Bluegrass Allergy Care
Lexington
Delricht Research Louisville
Louisville
Louisiana
Delricht Research Louisiana
Baton Rouge
Velocity Clinical Research, Lafayette
Lafayette
Delricht Research
New Orleans
Massachusetts
Boston Specialists
Boston
Maryland
Johns Hopkins Bayview Medical Center
Baltimore
Michigan
MI Skin Innovations
Northville
Missouri
DelRicht Research - Town Center Dermatology
Wildwood
North Carolina
Allergy Partners Clinical Research
Asheville
Delricht Research - Priority Care
Charlotte
Piedmont Healthcare
Statesville
New York
Vitality Clinical Trials
Woodbury
Ohio
Optima Research Boardman
Boardman
DOCS Dermatology Research
Canal Winchester
Bernstein Clinical Research Center
Cincinnati
Toledo Institute of Clinical Research
Toledo
South Carolina
AMR Myrtle Beach
Myrtle Beach
National Allergy and Asthma Research
North Charleston
Tennessee
Delricht Research Smyrna
Smyrna
Texas
Austin Regional Clinic ARC Clinical Research
Austin
Studies in Dermatology
Cypress
Western Sky Medical Research
El Paso
Delricht Research - Lockhard Matter Dermatology
Prosper
Utah
AMR Utah
Layton
Washington
Seattle Clinical Research Center
Seattle
Wisconsin
Allergy, Asthma, and Sinus Center
Greenfield
Other Locations
Canada
Dandelion Allergy Centre
Mississauga
Centre de Recherche Saint-Louis - Montréal
Montreal
Allergy Research Canada
Niagara Falls
Red Maple Trials
Ottawa
Centre de Recherche Saint-Louis
Québec
Japan
Mita Dermatology
Minato-ku
Dermatology and Ophthalmology Kume Clinic
Sakai
ThinkPark Dermatology Clinic
Shinagawa-ku
Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
Tachikawa
Osaka Medical and Pharmaceutical University Hospital
Takatsuki
Yoshikawa Skin Clinic
Takatsuki
Ikebukuro Nishiguchi Fukurou Dermatology
Toshima-ku
Time Frame
Start Date: 2025-03-20
Completion Date: 2026-05
Participants
Target number of participants: 160
Treatments
Experimental: Dose 1
Orally administered EVO756, dose 1
Experimental: Dose 2
Orally administered EVO756, dose 2
Experimental: Dose 3
Orally administered EVO756, dose 3
Placebo_comparator: Placebo control
Orally administered placebo control
Related Therapeutic Areas
Sponsors
Leads: Evommune, Inc.